Current opportunities and challenges of magnetic resonance spectroscopy, positron emission tomography, and mass spectrometry imaging for mapping cancer metabolism in vivo

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lin, Gigin ^a   Chung, Yuen Li ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER METABOLISM MAPPING; DYNAMIC NUCLEAR POLARIZATION MAGNETIC RESONANCE SPECTROSCOPY; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; MASS SPECTROMETRY; MASS SPECTROMETRY IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGICAL PROCEDURE; POSITRON EMISSION TOMOGRAPHY; ANIMAL; METABOLISM; NEOPLASM; PROCEDURES; RADIOGRAPHY;

ANIMALS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84897844765     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/625095     Document Type: Article

References (153)

1. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
2. Kaddurah-Daouk R., Kristal B. S., Weinshilboum R. M., Metabolomics: a global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology 2008 48 653 683 2-s2.0-41149162296 10.1146/annurev.pharmtox.48.113006.094715 (Pubitemid 351738167)
3. Warburg O., On the origin of cancer cells. Science 1956 123 3191 309 314 2-s2.0-12444279265
4. Gatenby R. A., Gillies R. J., A microenvironmental model of carcinogenesis. Nature Reviews Cancer 2008 8 1 56 61 2-s2.0-37549013776 10.1038/nrc2255
5. Rich P. R., The molecular machinery of Keilin's respiratory chain. Biochemical Society Transactions 2003 31 6 1095 1105 2-s2.0-0347419305 (Pubitemid 38030918)
6. Griffin J. L., Kauppinen R. A., Tumour metabolomics in animal models of human cancer. Journal of Proteome Research 2007 6 2 498 505 2-s2.0-33847370301 10.1021/pr060464h (Pubitemid 46340153)
7. Costello L. C., Franklin R. B., 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Molecular and Cellular Biochemistry 2005 280 1-2 1 8 2-s2.0-26844461245 10.1007/s11010-005-8841-8 (Pubitemid 41829794)
8. Elstrom R. L., Bauer D. E., Buzzai M., Karnauskas R., Harris M. H., Plas D. R., Zhuang H., Cinalli R. M., Alavi A., Rudin C. M., Thompson C. B., Akt stimulates aerobic glycolysis in cancer cells. Cancer Research 2004 64 11 3892 3899 2-s2.0-2542561169 10.1158/0008-5472.CAN-03-2904 (Pubitemid 38697301)
9. Plas D. R., Thompson C. B., Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005 24 50 7435 7442 2-s2.0-27844526600 10.1038/sj.onc.1209097 (Pubitemid 41637983)
10. Porstmann T., Santos C. R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J. R., Chung Y.-L., Schulze A., SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metabolism 2008 8 3 224 236 2-s2.0-50049116472 10.1016/j.cmet.2008.07.007
11. Kim J.-W., Dang C. V., Cancer's molecular sweet tooth and the warburg effect. Cancer Research 2006 66 18 8927 8930 2-s2.0-33749478922 10.1158/0008-5472.CAN-06-1501 (Pubitemid 44521105)
12. Shim H., Dolde C., Lewis B. C., Wu C.-S., Dang G., Jungmann R. A., Dalla-Favera R., Dang C. V., c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America 1997 94 13 6658 6663 2-s2.0-0030921103 10.1073/pnas.94.13.6658 (Pubitemid 27281920)
13. Downward J., Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003 3 1 11 22 2-s2.0-0037264633 10.1038/nrc969 (Pubitemid 37328883)
14. Telang S., Yalcin A., Clem A. L., Bucala R., Lane A. N., Eaton J. W., Chesney J., Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006 25 55 7225 7234 2-s2.0-33747487110 10.1038/sj.onc.1209709 (Pubitemid 44809088)
15. Vousden K. H., Ryan K. M., P53 and metabolism. Nature Reviews Cancer 2009 9 10 691 700 2-s2.0-70349459599 10.1038/nrc2715
16. Shackelford D. B., Shaw R. J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer 2009 9 8 563 575 2-s2.0-67749111502 10.1038/nrc2676
17. Wong K.-K., Engelman J. A., Cantley L. C., Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetics and Development 2010 20 1 87 90 2-s2.0-75849118878 10.1016/j.gde.2009.11.002
18. Al-Saffar N. M. S., Jackson L. E., Raynaud F. I., Clarke P. A., De Molina A. R., Lacal J. C., Workman P., Leach M. O., The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase α leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Research 2010 70 13 5507 5517 2-s2.0-77954358936 10.1158/0008-5472.CAN-09-4476
19. Denko N. C., Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer 2008 8 9 705 713 2-s2.0-50149097983 10.1038/nrc2468
20. Beloueche-Babari M., Jackson L. E., Al-Saffar N. M. S., Workman P., Leach M. O., Ronen S. M., Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Research 2005 65 8 3356 3363 2-s2.0-17144420870 (Pubitemid 40524620)
21. Jordan B. F., Black K., Robey I. F., Runquist M., Powis G., Gillies R. J., Metabolite changes in HT-29 xenograft tumors following HIF-1 α inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR in Biomedicine 2005 18 7 430 439 2-s2.0-27844601569 10.1002/nbm.977 (Pubitemid 41646184)
22. Kim J.-W., Tchernyshyov I., Semenza G. L., Dang C. V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 2006 3 3 177 185 2-s2.0-33644614520 10.1016/j.cmet.2006.02.002
23. Al-Saffar N. M. S., Troy H., de Molina A. R., Jackson L. E., Madhu B., Griffiths J. R., Leach M. O., Workman P., Lacal J. C., Judson I. R., Chung Y.-L., Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Research 2006 66 1 427 434 2-s2.0-31544473808 10.1158/0008-5472.CAN-05-1338 (Pubitemid 43166051)
24. Evans A., Bates V., Troy H., Hewitt S., Holbeck S., Chung Y.-L., Phillips R., Stubbs M., Griffiths J., Airley R., Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemotherapy and Pharmacology 2008 61 3 377 393 2-s2.0-37249067628 10.1007/s00280-007-0480-1 (Pubitemid 350275973)
25. Sonveaux P., Copetti T., de Saedeleer C. J., Végran F., Verrax J., Kennedy K. M., Moon E. J., Dhup S., Danhier P., Frérart F., Gallez B., Ribeiro A., Michiels C., Dewhirst M. W., Feron O., Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE 2012 7 3 2-s2.0-84858120137 10.1371/journal.pone.0033418 e33418
26. Yauch R. L., Settleman J., Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Current Opinion in Genetics and Development 2012 22 1 45 49 2-s2.0-84858439267 10.1016/j.gde.2012.01.003
27. Vander Heiden M. G., Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery 2011 10 9 671 684 2-s2.0-80052242132 10.1038/nrd3504
28. Tennant D. A., Durán R. V., Gottlieb E., Targeting metabolic transformation for cancer therapy. Nature Reviews Cancer 2010 10 4 267 277 2-s2.0-77949967131 10.1038/nrc2817
29. Evelhoch J., Garwood M., Vigneron D., Knopp M., Sullivan D., Menkens A., Clarke L., Liu G., Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Research 2005 65 16 7041 7044 2-s2.0-23844456531 10.1158/0008-5472.CAN-05-0674 (Pubitemid 41161229)
30. Workman P., Aboagye E. O., Chung Y.-L., Griffiths J. R., Hart R., Leach M. O., Maxwell R. J., McSheehy P. M. J., Price P. M., Zweit J., Minimally invasive Pharmacokinetic and Pharmacodynamic Technologies in hypothesis-testing clinical trials of innovative therapies. Journal of the National Cancer Institute 2006 98 9 580 598 2-s2.0-33646457229 10.1093/jnci/djj162 (Pubitemid 43904842)
31. Gerlinger M., Rowan A. J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N. Q., Butler A., Jones D., Raine K., Latimer C., Santos C. R., Nohadani M., Eklund A. C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P. A., Swanton C., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 2012 366 10 883 892 2-s2.0-84857839394 10.1056/NEJMoa1113205
32. Seyfried T. N., Shelton L. M., Cancer as a metabolic disease. Nutrition and Metabolism 2010 7, article 7 2-s2.0-77649277719 10.1186/1743-7075-7-7
33. Gatenby R. A., Gillies R. J., Why do cancers have high aerobic glycolysis? Nature Reviews Cancer 2004 4 11 891 899 2-s2.0-8144228566 10.1038/nrc1478 (Pubitemid 39472955)
34. Israël M., Schwartz L., The metabolic advantage of tumor cells. Molecular Cancer 2011 10, article 70 2-s2.0-79957941802 10.1186/1476-4598-10-70
35. Feron O., Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and Oncology 2009 92 3 329 333 2-s2.0-69949124867 10.1016/j.radonc.2009.06.025
36. Icard P., Lincet H., A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochimica et Biophysica Acta 2012 1826 2 423 433
37. Semenza G. L., Tumor metabolism: cancer cells give and take lactate. The Journal of Clinical Investigation 2008 118 12 3835 3837 2-s2.0-57449115616 10.1172/JCI37373
38. Sonveaux P., Végran F., Schroeder T., Wergin M. C., Verrax J., Rabbani Z. N., De Saedeleer C. J., Kennedy K. M., Diepart C., Jordan B. F., Kelley M. J., Gallez B., Wahl M. L., Feron O., Dewhirst M. W., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation 2008 118 12 3930 3942 2-s2.0-57449097020 10.1172/JCI36843
39. Griffin J. L., Kauppinen R. A., A metabolomics perspective of human brain tumours. The FEBS Journal 2007 274 5 1132 1139 2-s2.0-33846981150 10.1111/j.1742-4658.2007.05676.x
40. Swanson M. G., Zektzer A. S., Tabatabai Z. L., Simko J., Jarso S., Keshari K. R., Schmitt L., Carroll P. R., Shinohara K., Vigneron D. B., Kurhanewicz J., Quantitative analysis of prostate metabolites using1H HR-MAS spectroscopy. Magnetic Resonance in Medicine 2006 55 6 1257 1264 2-s2.0-33744965485 10.1002/mrm.20909 (Pubitemid 43856762)
41. Bartella L., Huang W., Proton (1H) MR spectroscopy of the breast. Radiographics 2007 27 supplement 1 S241 S252 2-s2.0-36148947946 10.1148/rg.27si075504
42. Dowling C., Bollen A. W., Noworolski S. M., McDermott M. W., Barbaro N. M., Day M. R., Henry R. G., Chang S. M., Dillon W. P., Nelson S. J., Vigneron D. B., Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. American Journal of Neuroradiology 2001 22 4 604 612 2-s2.0-0035044380 (Pubitemid 32318684)
43. Mukherji S. K., Schiro S., Castillo M., Kwock L., Muller K. E., Blackstock W., Proton MR spectroscopy of squamous cell carcinoma of the extracranial head and neck: in vitro and in vivo studies. American Journal of Neuroradiology 1997 18 6 1057 1072 2-s2.0-0031546097 (Pubitemid 30412127)
44. Seitz M., Shukla-Dave A., Bjartell A., Touijer K., Sciarra A., Bastian P. J., Stief C., Hricak H., Graser A., Functional magnetic resonance imaging in prostate cancer. European Urology 2009 55 4 801 814 2-s2.0-60249085103 10.1016/j.eururo.2009.01.027
45. Alusta P., Im I., Pearce B. A., Beger R. D., Kretzer R. M., Buzatu D. A., Wilkes J. G., Improving proton MR spectroscopy of brain tissue for noninvasive diagnostics. Journal of Magnetic Resonance Imaging 2010 32 4 818 829 2-s2.0-79952202526
46. Mahon M. M., Cox I. J., Dina R., Soutter W. P., McIndoe G. A., Williams A. D., DeSouza N. M., 1H Magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: in vivo-ex vivo profiles and effect of tumor load. Journal of Magnetic Resonance Imaging 2004 19 3 356 364 2-s2.0-1542319072 10.1002/jmri.20012 (Pubitemid 38294777)
47. Nelson S. J., Kurhanewicz J., Vigneron D. B., Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Science Translational Medicine 2013 5 198 198ra08
48. Zhu A., Lee D., Shim H., Metabolic positron emission tomography imaging in cancer detection and therapy response. Seminars in Oncology 2011 38 1 55 69 2-s2.0-79952159653 10.1053/j.seminoncol.2010.11.012
49. Ng S.-H., Yen T.-C., Liao C.-T., Chang J. T.-C., Chan S.-C., Ko S.-F., Wang H.-M., Wong H.-F., 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. Journal of Nuclear Medicine 2005 46 7 1136 1143 2-s2.0-23844455665 (Pubitemid 43741075)
50. van den Abbeele A. D., Badawi R. D., Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). European Journal of Cancer 2002 38 supplement 5 S60 65 2-s2.0-0036769690
51. Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., Nuyts J., Martens M., Van Den Borne B., Cole P., Sciot R., Dumez H., Silberman S., Mortelmans L., Van Oosterom A., 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). European Journal of Cancer 2003 39 14 2012 2020 2-s2.0-0041984595 10.1016/S0959-8049(03)00073-X (Pubitemid 37297757)
52. Sunaga N., Oriuchi N., Kaira K., Yanagitani N., Tomizawa Y., Hisada T., Ishizuka T., Endo K., Mori M., Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008 59 2 203 210 2-s2.0-38649097511 10.1016/j.lungcan.2007.08.012 (Pubitemid 351173409)
53. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., Hicks R. J., The impact of PET/CT in the management of recurrent ovarian cancer. Gynecologic Oncology 2006 103 1 271 276 2-s2.0-33748534206 10.1016/j.ygyno.2006.03.004 (Pubitemid 44374699)
54. Goh B. K. P., Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Annals of Surgery 2006 243 5 709 710 2-s2.0-33746223212 10.1097/01.sla. 0000216766.93589.34 (Pubitemid 44305599)
55. Schöder H., Herrmann K., Gönen M., Hricak H., Eberhard S., Scardino P., Scher H. I., Larson S. M., 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clinical Cancer Research 2005 11 13 4761 4769 2-s2.0-27644562208 10.1158/1078-0432.CCR-05-0249 (Pubitemid 41557196)
56. Ho K.-C., Lin G., Wang J.-J., Lai C.-H., Chang C.-J., Yen T.-C., Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging 2009 36 2 200 208 2-s2.0-58849087962 10.1007/s00259-008-0936-5
57. Yen T.-C., See L.-C., Chang T.-C., Huang K.-G., Ng K.-K., Tang S. G., Chang Y.-C., Hsueh S., Tsai C.-S., Hong J.-H., Lin C.-T., Chao A., Shih-Ya M., Lin W.-J., Fu Y.-K., Fan C.-C., Lai C.-H., Defining the priority of using 18F-FDG PET for recurrent cervical cancer. Journal of Nuclear Medicine 2004 45 10 1632 1639 2-s2.0-16544387519 (Pubitemid 47618468)
58. Schwartz S. A., Weil R. J., Thompson R. C., Shyr Y., Moore J. H., Toms S. A., Johnson M. D., Caprioli R. M., Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Research 2005 65 17 7674 7681 2-s2.0-24744457360 10.1158/0008-5472.CAN-04-3016 (Pubitemid 41297241)
59. Patel S. A., Barnes A., Loftus N., Martin R., Sloan P., Thakker N., Goodacre R., Imaging mass spectrometry using chemical inkjet printing reveals differential protein expression in human oral squamous cell carcinoma. The Analyst 2009 134 2 301 307 2-s2.0-58949102239 10.1039/b812533c
60. Groseclose M. R., Massion P. P., Chaurand P., Caprioli R. M., High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008 8 18 3715 3724 2-s2.0-53549111100 10.1002/pmic.200800495
61. Rauser S., Marquardt C., Balluff B., Deininger S.-O., Albers C., Belau E., Hartmer R., Suckau D., Specht K., Ebert M. P., Schmitt M., Aubele M., Hfler H., Walch A., Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. Journal of Proteome Research 2010 9 4 1854 1863 2-s2.0-77950661168 10.1021/pr901008d
62. Morita Y., Ikegami K., Goto-Inoue N., Hayasaka T., Zaima N., Tanaka H., Uehara T., Setoguchi T., Sakaguchi T., Igarashi H., Sugimura H., Setou M., Konno H., Imaging mass spectrometry of gastric carcinoma in formalin-fixed paraffin-embedded tissue microarray. Cancer Science 2010 101 1 267 273 2-s2.0-71849100285 10.1111/j.1349-7006.2009.01384.x
63. Djidja M.-C., Claude E., Snel M. F., Scriven P., Francese S., Carolan V., Clench M. R., MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. Journal of Proteome Research 2009 8 10 4876 4884 2-s2.0-70349974835 10.1021/pr900522m
64. Oppenheimer S. R., Mi D., Sanders M. E., Caprioli R. M., Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. Journal of Proteome Research 2010 9 5 2182 2190 2-s2.0-77952035951 10.1021/pr900936z
65. Lemaire R., Menguellet S. A., Stauber J., Marchaudon V., Lucot J.-P., Collinet P., Farine M.-O., Vinatier D., Day R., Ducoroy P., Salzet M., Fournier I., Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, reg alpha fragment, is a new potential ovary cancer biomarker. Journal of Proteome Research 2007 6 11 4127 4134 2-s2.0-36348988577 10.1021/pr0702722 (Pubitemid 350158491)
66. Cazares L. H., Troyer D., Mendrinos S., Lance R. A., Nyalwidhe J. O., Beydoun H. A., Clements M. A., Drake R. R., Semmes O. J., Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clinical Cancer Research 2009 15 17 5541 5551 2-s2.0-69949095925 10.1158/1078-0432.CCR-08-2892
67. Nicholson J. K., Lindon J. C., Holmes E., 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999 29 11 1181 1189 2-s2.0-0032694577
68. Fiehn O., Kopka J., Dörmann P., Altmann T., Trethewey R. N., Willmitzer L., Metabolite profiling for plant functional genomics. Nature Biotechnology 2000 18 11 1157 1161 2-s2.0-0033757963 10.1038/81137
69. Dunn W. B., Broadhurst D. I., Atherton H. J., Goodacre R., Griffin J. L., Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews 2011 40 1 387 426 2-s2.0-78650315006 10.1039/b906712b
70. Lenz E. M., Wilson I. D., Analytical strategies in metabonomics. Journal of Proteome Research 2007 6 2 443 458 2-s2.0-33847358695 10.1021/pr0605217 (Pubitemid 46340149)
71. Psychogios N., Hau D. D., Peng J., Guo A. C., Mandal R., Bouatra S., Sinelnikov I., Krishnamurthy R., Eisner R., Gautam B., Young N., Xia J., Knox C., Dong E., Huang P., Hollander Z., Pedersen T. L., Smith S. R., Bamforth F., Greiner R., McManus B., Newman J. W., Goodfriend T., Wishart D. S., The human serum metabolome. PLoS ONE 2011 6 2 2-s2.0-79951892537 10.1371/journal.pone. 0016957 e16957
72. Griffiths J. R., Chung Y. L., Harris R. K., Wasylishen R. E., Metabolomic studies on cancer and on anticancer drugs by NMR ex vivo. Encyclopedia of Magnetic Resonance 2011 Chichester, UK John Wiley & Sons
73. Brown M. V., McDunn J. E., Gunst P. R., Smith E. M., Milburn M. V., Troyer D. A., Lawton K. A., Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Medicine 2012 4 4, article 33 2-s2.0-84860484490 10.1186/gm332
74. Glunde K., Bhujwalla Z. M., Metabolic tumor imaging using magnetic resonance spectroscopy. Seminars in Oncology 2011 38 1 26 41 2-s2.0-79952154676 10.1053/j.seminoncol.2010.11.001
75. Slichter C. P., Principles of Magnetic Resonance 1990 3rd New York, NY, USA Springer
76. Frahm J., Bruhn H., Gyngell M. L., Merboldt K. D., Hanicke W., Sauter R., Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magnetic Resonance in Medicine 1989 9 1 79 93 2-s2.0-0024493728 (Pubitemid 19044561)
77. Bottomley P. A., Spatial localization in NMR spectroscopy in vivo. Annals of the New York Academy of Sciences 1987 508 333 348 2-s2.0-0023636904
78. Ordidge R. J., Bowley R. M., McHale G., A general approach to selection of multiple cubic volume elements using the ISIS technique. Magnetic Resonance in Medicine 1988 8 3 323 331 2-s2.0-0023696866
79. Brown T. R., Kincaid B. M., Ugurbil K., NMR chemical shift imaging in three dimensions. Proceedings of the National Academy of Sciences of the United States of America 1982 79 11 I 3523 3526 2-s2.0-0001655809 (Pubitemid 12011397)
80. Glunde K., Jie C., Bhujwalla Z. M., Molecalar causes of tile aberrant choline phospholipid metabolism in breast cancer. Cancer Research 2004 64 12 4270 4276 2-s2.0-3042562283 10.1158/0008-5472.CAN-03-3829 (Pubitemid 38802433)
81. Gillies R. J., Morse D. L., In vivo magnetic resonance spectroscopy in cancer. Annual Review of Biomedical Engineering 2005 7 287 326 2-s2.0-23844457954 10.1146/annurev.bioeng.7.060804.100411 (Pubitemid 41170190)
82. Hakumäki J. M., Poptani H., Sandmair A.-M., Ylä-Herttuala S., Kauppinen R. A., 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nature Medicine 1999 5 11 1323 1327 2-s2.0-0032590214 10.1038/15279 (Pubitemid 29535613)
83. Al-Saffar N. M. S., Titley J. C., Robertson D., Clarke P. A., Jackson L. E., Leach M. O., Ronen S. M., Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. British Journal of Cancer 2002 86 6 963 970 2-s2.0-0037128692 10.1038/sj.bjc.6600188 (Pubitemid 34271034)
84. Schmitz J. E., Kettunen M. I., Hu D.-E., Brindle K. M., 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magnetic Resonance in Medicine 2005 54 1 43 50 2-s2.0-21244495995 10.1002/mrm.20529 (Pubitemid 40898395)
85. Griffin J. L., Lehtimäki K. K., Valonen P. K., Gröhn O. H. J., Kettunen M. I., Ylä-Herttuala S., Pitkänen A., Nicholson J. K., Kauppinen R. A., Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Research 2003 63 12 3195 3201 2-s2.0-0038745622 (Pubitemid 36735872)
86. Okunieff P. G., Koutcher J. A., Gerweck L., Tumor size dependent changes in a murine fibrosarcoma: use of in vivo 31P NMR for non-invasive evaluation of tumor metabolic status. International Journal of Radiation Oncology Biology Physics 1986 12 5 793 799 2-s2.0-0022486661 (Pubitemid 16033478)
87. Tozer G. M., Griffiths J. R., The contribution made by cell death and oxygenation to 31P MRS observations of tumour energy metabolism. NMR in Biomedicine 1992 5 5 279 289 2-s2.0-0026919666
88. Wolf W., Presant C. A., Waluch V., 19F-MRS studies of fluorinated drugs in humans. Advanced Drug Delivery Reviews 2000 41 1 55 74 2-s2.0-0033623840 10.1016/S0169-409X(99)00056-3
89. Chung Y.-L., Troy H., Judson I. R., Leek R., Leach M. O., Stubbs M., Harris A. L., Griffiths J. R., Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Clinical Cancer Research 2004 10 11 3863 3870 2-s2.0-2542521699 10.1158/1078-0432.CCR-03-0237 (Pubitemid 38697622)
90. Li C., Penet M.-F., Winnard P. Jr., Artemov D., Bhujwalla Z. M., Image-guided enzyme/prodrug cancer therapy. Clinical Cancer Research 2008 14 2 515 522 2-s2.0-38949180291 10.1158/1078-0432.CCR-07-1837 (Pubitemid 351226121)
91. Hall E. L., Stephenson M. C., Price D., Morris P. G., Methodology for improved detection of low concentration metabolites in MRS: optimised combination of signals from multi-element coil arrays. NeuroImage 2014 86 35 42 10.1016/j.neuroimage.2013.04.077
92. Ardenkjær-Larsen J. H., Fridlund B., Gram A., Hansson G., Hansson L., Lerche M. H., Servin R., Thaning M., Golman K., Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10158 10163 2-s2.0-0042763165 10.1073/pnas.1733835100 (Pubitemid 37071849)
93. Wilson D. M., Keshari K. R., Larson P. E. Z., Chen A. P., Hu S., Criekinge M. V., Bok R., Nelson S. J., MacDonald J. M., Vigneron D. B., Kurhanewicz J., Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. Journal of Magnetic Resonance 2010 205 1 141 147 2-s2.0-77955338803 10.1016/j.jmr.2010.04.012
94. Witney T. H., Kettunen M. I., Hu D.-E., Gallagher F. A., Bohndiek S. E., Napolitano R., Brindle K. M., Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. British Journal of Cancer 2010 103 9 1400 1406 2-s2.0-78049307949 10.1038/sj.bjc.6605945
95. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Research 2006 66 22 10855 10860 2-s2.0-33845292936 10.1158/0008-5472.CAN-06-2564 (Pubitemid 44876982)
96. Kurhanewicz J., Vigneron D. B., Brindle K., Chekmenev E. Y., Comment A., Cunningham C. H., DeBerardinis R. J., Green G. G., Leach M. O., Rajan S. S., Rizi R. R., Ross B. D., Warren W. S., Malloy C. R., Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011 13 2 81 97 2-s2.0-79951507755 10.1593/neo.101102
97. 13C magnetic resonance imaging and spectroscopy. Nature Medicine 2007 13 11 1382 1387 2-s2.0-35948970970 10.1038/nm1650 (Pubitemid 350073590)
98. Chen A. P., Chu W., Gu Y. P., Cunnhingham C. H., Probing early tumor response to radiation therapy using hyperpolarized [1-(1)(3)C]pyruvate in MDA-MB-231 xenografts. PLoS ONE 2013 8 2 e56551
99. 13C MR metabolic imaging. Journal of Magnetic Resonance Imaging 2011 33 6 1284 1290 2-s2.0-79958244879 10.1002/jmri.22563
100. 13C magnetic resonance spectroscopy. Cancer Research 2010 70 4 1296 1305 2-s2.0-76749161366 10.1158/0008-5472.CAN-09-2251
101. 13C. The British Journal of Radiology 2003 76 2 S118 S127 2-s2.0-8844271662 10.1259/bjr/26631666 (Pubitemid 39530305)
102. Hill D. K., Jamin Y., Orton M. R., (1)H NMR and hyperpolarized (1)(3)C NMR assays of pyruvate-lactate: a comparative study. NMR in Biomedicine 2013 26 10 1321 1325
103. 13C magnetic resonance spectroscopy data. PLoS ONE 2013 8 9 e71996
104. 13C-labelled bicarbonate. Nature 2008 453 7197 940 943 2-s2.0-45149112158 10.1038/nature07017 (Pubitemid 351832568)
105. Gallagher F. A., Kettunen M. I., Hu D.-E., Jensen P. R., Zandt R. I., Karlsson M., Gisselsson A., Nelson S. K., Witney T. H., Bohndiek S. E., Hansson G., Peitersen T., Lerche M. H., Brindle K. M., Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proceedings of the National Academy of Sciences of the United States of America 2009 106 47 19801 19806 2-s2.0-73949133557 10.1073/pnas.0911447106
106. Nelson S. J., Kurhanewicz J., Vigneron D. B., Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Science Translational Medicine 2013 5 198 198ra08
107. Kapoor V., McCook B. M., Torok F. S., An introduction to PET-CT imaging. Radiographics 2004 24 2 523 543 2-s2.0-1842781646 (Pubitemid 38470893)
108. Macheda M. L., Rogers S., Best J. D., Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology 2005 202 3 654 662 2-s2.0-12944262229 10.1002/jcp.20166 (Pubitemid 40175840)
109. Maschauer S., Prante O., Hoffmann M., Deichen J. T., Kuwert T., Characterization of 18F-FDG uptake in human endothelial cells in vitro. Journal of Nuclear Medicine 2004 45 3 455 460 2-s2.0-2342575613 (Pubitemid 47618621)
110. Wood K. A., Hoskin P. J., Saunders M. I., Positron emission tomography in oncology: a review. Clinical Oncology 2007 19 4 237 255 2-s2.0-34047269955 10.1016/j.clon.2007.02.001 (Pubitemid 46547277)
111. Plathow C., Weber W. A., Tumor cell metabolism imaging. Journal of Nuclear Medicine 2008 49 supplement 2 43S 63S (Pubitemid 351948036)
112. Grassi I., Nanni C., Allegri V., The clinical use of PET with (11)C-acetate. American Journal of Nuclear Medicine and Molecular Imaging 2012 2 1 33 47
113. Glaudemans A. W., Enting R. H., Heesters M. A., Value of 11C-methionine PET in imaging brain tumours and metastases. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 4 615 635 10.1007/s00259-012-2295-5
114. Hausmann D., Bittencourt L. K., Attenberger U. I., Diagnostic accuracy of 18F choline PET/CT using time-of-flight reconstruction algorithm in prostate cancer patients with biochemical recurrence. Clinical Nuclear Medicine 2013
115. Soloviev D., Lewis D., Honess D., Aboagye E., [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. European Journal of Cancer 2012 48 4 416 424 2-s2.0-84857059339 10.1016/j.ejca.2011.11.035
116. Paolillo V., Yeh H. H., Mukhopadhyay U., Gelovani J. G., Alauddin M. M., Improved detection and measurement of low levels of [18F]fluoride metabolized from [18F]-labeled pyrimidine nucleoside analogues in biological samples. Nuclear Medicine and Biology 2011 38 8 1129 1134 2-s2.0-82655172516 10.1016/j.nucmedbio.2011.05.008
117. 13C MRI and PET: in vivo tumor biochemistry. Journal of Nuclear Medicine 2011 52 9 1333 1336 2-s2.0-80052627432 10.2967/jnumed.110.085258
118. Culver J., Akers W., Achilefu S., Multimodality molecular imaging with combined optical and SPECT/PET modalities. Journal of Nuclear Medicine 2008 49 2 169 172 2-s2.0-38949163790 10.2967/jnumed.107.043331 (Pubitemid 351225675)
119. Albers M. J., Bok R., Chen A. P., Cunningham C. H., Zierhut M. L., Zhang V. Y., Kohler S. J., Tropp J., Hurd R. E., Yen Y.-F., Nelson S. J., Vigneron D. B., Kurhanewicz J., Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Research 2008 68 20 8607 8615 2-s2.0-54249093810 10.1158/0008-5472.CAN-08-0749
120. Buchbender C., Heusner T. A., Lauenstein T. C., Bockisch A., Antoch G., Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. Journal of Nuclear Medicine 2012 53 6 928 938
121. Bohndiek S. E., Brindle K. M., Imaging and 'omic methods for the molecular diagnosis of cancer. Expert Review of Molecular Diagnostics 2010 10 4 417 434 2-s2.0-77952495880 10.1586/erm.10.20
122. 11C-choline positron emission tomography. Cancer Research 2013 73 5 1470 1480 10.1158/0008-5472.CAN-12-2532
123. Smith T. A., Appleyard M. V., Sharp S., Fleming I. N., Murray K., Thompson A. M., Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. Cancer Chemotherapy and Pharmacology 2013 71 2 473 480 10.1007/s00280-012-2032-6
124. Wolf W., The unique potential for noninvasive imaging in modernizing drug development and in transforming therapeutics: PET/MRI/MRS. Pharmaceutical Research 2011 28 3 490 493 2-s2.0-79952485613 10.1007/s11095-010-0293-5
125. Jansen J. F. A., Schöder H., Lee N. Y., Stambuk H. E., Wang Y., Fury M. G., Patel S. G., Pfister D. G., Shah J. P., Koutcher J. A., Shukla-Dave A., Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. International Journal of Radiation Oncology Biology Physics 2012 82 1 299 307 2-s2.0-83955165975 10.1016/j.ijrobp.2010.11.022
126. Testa C., Schiavina R., Lodi R., Salizzoni E., Corti B., Farsad M., Kurhanewicz J., Manferrari F., Brunocilla E., Tonon C., Monetti N., Castellucci P., Fanti S., Coe M., Grigioni W. F., Martorana G., Canini R., Barbiroli B., Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007 244 3 797 806 2-s2.0-34548083158 10.1148/radiol.2443061063 (Pubitemid 47292091)
127. Panebianco V., Sciarra A., Lisi D., Galati F., Buonocore V., Catalano C., Gentile V., Laghi A., Passariello R., Prostate cancer: 1HMRS-DCEMR at 3 T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). European Journal of Radiology 2012 81 4 700 708 2-s2.0-84858287835 10.1016/j.ejrad.2011.01.095
128. Tozaki M., Hoshi K., 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. American Journal of Roentgenology 2010 194 5 1384 1390 2-s2.0-77951968011 10.2214/AJR.09.3431
129. Katz-Brull R., Lavin P. T., Lenkinski R. E., Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. Journal of the National Cancer Institute 2002 94 16 1197 1203 2-s2.0-0037151369 (Pubitemid 34993869)
130. Kumiko A., Reiichi I., Yuki N., Tsutomu M., Yoshihiro T., Jota I., Norio N., Tsuyoshi M., Norio A., Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions. Nippon Acta Radiologica 2004 64 3 121 126 2-s2.0-2942555606 (Pubitemid 41373767)
131. Hourani R., Brant L. J., Rizk T., Weingart J. D., Barker P. B., Horská A., Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? American Journal of Neuroradiology 2008 29 2 366 372 2-s2.0-39649098259 10.3174/ajnr.A0810 (Pubitemid 351287898)
132. Smith E. A., Carlos R. C., Junck L. R., Tsien C. I., Elias A., Sundgren P. C., Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. American Journal of Roentgenology 2009 192 2 W45 W52 2-s2.0-59349093308 10.2214/AJR.07.3934
133. Sung S. A., Kim M.-J., Joon S. L., Hong H.-S., Yong E. C., Choi J.-Y., Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010 255 2 459 466 2-s2.0-77951438377 10.1148/radiol.10091388
134. Hwang J., Kim S. H., Lee M. W., Lee J. Y., Small, (≤ = 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. The The British Journal of Radiology 2012 85 1015 e314 e322
135. Park M. J., Kim Y. K., Lee M. W., Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012 264 3 761 770
136. Park J.-W., Ji H. K., Seok K. K., Keon W. K., Kyung W. P., Choi J.-I., Woo J. L., Kim C.-M., Byung H. N., A prospective evaluation of18F-FDG and11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. Journal of Nuclear Medicine 2008 49 12 1912 1921 2-s2.0-57149101558 10.2967/jnumed.108.055087
137. Talbot J.-N., Fartoux L., Balogova S., Nataf V., Kerrou K., Gutman F., Huchet V., Ancel D., Grange J.-D., Rosmorduc O., Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of18F-fluorocholine and18F-FDG in patients with cirrhosis or chronic liver disease. Journal of Nuclear Medicine 2010 51 11 1699 1706 2-s2.0-79851493457 10.2967/jnumed.110.075507
138. Menzel M. I., Farrell E. V., Janich M. A., Multimodal assessment of in vivo metabolism with hyperpolarized [1-13C]MR spectroscopy and 18F-FDG PET imaging in hepatocellular carcinoma tumor-bearing rats. Journal of Nuclear Medicine 2013 54 7 1113 1119
139. Srirajaskanthan R., Kayani I., Quigley A. M., Soh J., Caplin M. E., Bomanji J., The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Journal of Nuclear Medicine 2010 51 6 875 882 2-s2.0-77953928471 10.2967/jnumed.109.066134
140. Ljungberg M., Westberg G., Vikhoff-Baaz B., 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases. Acta Radiologica 2012 53 10 1118 1126
141. Sullentrop F., Hahn J., Moka D., In vitro and in vivo (1)H-MR spectroscopic examination of the renal cell carcinoma. International Journal of Biomedical Science 2012 8 2 94 108
142. Keshari K. R., Sriram R., Koelsch B. L., Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Research 2013 73 2 529 538
143. Cornett D. S., Mobley J. A., Dias E. C., Andersson M., Arteaga C. L., Sanders M. E., Caprioli R. M., A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Molecular and Cellular Proteomics 2006 5 10 1975 1983 2-s2.0-33750604754 10.1074/mcp.M600119-MCP200 (Pubitemid 44688205)
144. Nimesh S., Mohottalage S., Vincent R., Kumarathasan P., Current status and future perspectives of mass spectrometry imaging. International Journal of Molecular Sciences 2013 14 6 11277 11301 10.3390/ijms140611277
145. Miura D., Fujimura Y., Wariishi H., In situ metabolomic mass spectrometry imaging: recent advances and difficulties. Journal of Proteomics 2012 75 16 5052 5060 2-s2.0-84857385879 10.1016/j.jprot.2012.02.011
146. Crecelius A. C., Cornett D. S., Caprioli R. M., Williams B., Dawant B. M., Bodenheimer B., Three-dimensional visualization of protein expression in mouse brain structures using imaging mass spectrometry. Journal of the American Society for Mass Spectrometry 2005 16 7 1093 1099 2-s2.0-20444490835 10.1016/j.jasms.2005.02.026 (Pubitemid 40828790)
147. Harada T., Yuba-Kubo A., Sugiura Y., Zaima N., Hayasaka T., Goto-Inoue N., Wakui M., Suematsu M., Takeshita K., Ogawa K., Yoshida Y., Setou M., Visualization of volatile substances in different organelles with an atmospheric-pressure mass microscope. Analytical Chemistry 2009 81 21 9153 9157 2-s2.0-70350633041 10.1021/ac901872n
148. Sun G., Yang K., Zhao Z., Guan S., Han X., Gross R. W., Matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis of cellular glycerophospholipids enabled by multiplexed solvent dependent analyte-matrix interactions. Analytical Chemistry 2008 80 19 7576 7585 2-s2.0-54749108383 10.1021/ac801200w
149. Chughtai K., Jiang L., Greenwood T. R., Glunde K., Heeren R. M., Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models. Journal of Lipid Research 2013 54 2 333 344
150. Miura D., Fujimura Y., Yamato M., Hyodo F., Utsumi H., Tachibana H., Wariishi H., Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Analytical Chemistry 2010 82 23 9789 9796 2-s2.0-78649699613 10.1021/ac101998z
151. Hattori K., Kajimura M., Hishiki T., Nakanishi T., Kubo A., Nagahata Y., Ohmura M., Yachie-Kinoshita A., Matsuura T., Morikawa T., Nakamura T., Setou M., Suematsu M., Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry. Antioxidants and Redox Signaling 2010 13 8 1157 1167 2-s2.0-77956325355 10.1089/ars.2010.3290
152. Calavia R., Annanouch F. E., Correig X., Yanes O., Nanostructure Initiator Mass Spectrometry for tissue imaging in metabolomics: future prospects and perspectives. Journal of Proteomics 2012 75 16 5061 5068
153. Northen T. R., Yanes O., Northen M. T., Marrinucci D., Uritboonthai W., Apon J., Golledge S. L., Nordström A., Siuzdak G., Clathrate nanostructures for mass spectrometry. Nature 2007 449 7165 1033 1036 2-s2.0-35548992879 10.1038/nature06195 (Pubitemid 350017585)